Soleno Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Soleno Therapeutics Inc SLNO.OQ reported a quarterly adjusted loss of 9 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -57 cents. The mean expectation of nine analysts for the quarter was for a loss of 46 cents per share. Wall Street expected results to range from -83 cents to -21 cents per share.

• Revenue was $32.66 million​; analysts expected $25.14 million.

• Soleno Therapeutics Inc's reported EPS for the quarter was a loss of 9 cents​.

• The company reported a quarterly loss of $4.71 million.

• Soleno Therapeutics Inc shares had fallen by 2.6% this quarter and gained 81.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 48.7% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Soleno Therapeutics Inc is $115.00, about 29% above its last closing price of $81.63

This summary was machine generated from LSEG data August 6 at 09:02 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)